Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

IBMX

IBMX
Contact us for more batch information
Select Batch
Purity:100%
Resource Download

IBMX

Catalog No. T1713Cas No. 28822-58-4
IBMX (Methylisobutylxanthine) is a broad-spectrum phosphodiesterase (PDE) inhibitor with inhibitory activity against PDE3, PDE4, and PDE5 (IC50=6.5/26.3/31.7 μM). IBMX enhances the intracellular cAMP level.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
25 mg$33In Stock
50 mg$47In Stock
100 mg$58In Stock
200 mg$105In Stock
1 mL x 10 mM (in DMSO)$50In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "IBMX"

Product Introduction

Bioactivity
Description
IBMX (Methylisobutylxanthine) is a broad-spectrum phosphodiesterase (PDE) inhibitor with inhibitory activity against PDE3, PDE4, and PDE5 (IC50=6.5/26.3/31.7 μM). IBMX enhances the intracellular cAMP level.
In vitro
METHODS: CCDs isolated from HK-fed rats were pretreated with IBMX (100 μM) for 20 min and examined the effect of ANG II or cGMP on channel activity.
RESULTS: IBMX activated ROMK channels and prevented further channel activation by ANG II. [1]
METHODS: Primary cultures of guinea pig TSMC were assayed for the effect of KMUP-1 on cAMP and cGMP levels in the presence of IBMX (100 μM).
RESULTS: IBMX and KMUP-1 significantly increased cAMP and cGMP levels. The effect of KMUP-1 alone on cAMP and cGMP levels was not significantly different from that in the presence of IBMX. [2]
METHODS: Mammalian cell CHO was treated with IBMX (10-1000 μM) and whole cell currents were measured using the membrane clamp technique.
RESULTS: A steady-state dose-response curve for the effect of IBMX on THIK-1 currents could be fitted with a Hill coefficient of 1 and an IC50 of 120 μM.[3]
In vivo
METHODS: To test the metabolic effects on mice, IBMX (1 mg/kg) was injected subcutaneously into mice twice daily for seven days.
RESULTS: IBMX significantly increased blood glucose levels in mice (blood glucose, mg/dl, control=141, IBMX=210). [4]
METHODS: To test the metabolic effects on hyperglycemic mice, glucose (0.5 g/kg) and IBMX (1 mg/kg) were injected i.v. in femoral veins into Wistar rats.
RESULTS: In hyperglycemic rats, IBMX lowered blood glucose, IBMX did not change plasma insulin levels, and IBMX decreased hepatic glycogen stores. [4]
Cell Research
Intracellular cyclic GMP and cyclic AMP concentrations in guinea-pig TSMCs were assayed as previously described. In brief, cells were grown in 24-well plates 10^5 cells per well. At confluence, monolayer cells were washed with phosphate buffer solution (PBS) and then incubated with KMUP-1 (0.1–100 μM) in the presence of 100 μM IBMX for 20 min. Incubation was terminated by the addition of 10% trichloroacetic acid (TCA). Cell suspensions were sonicated and then centrifuged at 2500 × g for 15 min at 4°C. To remove TCA, the supernatants were extracted three times with 5 volumes of water-saturated diethyl ether. Then, the supernatants were lyophilized and the cyclic GMP or AMP of each sample was determined by using commercially available radioimmunoassay kits [1].
Animal Research
Male mice (25-35 g), obtained from the animal house of Faculty of Medicine, were kept in controlled environmental conditions (temperature: 23±2 oC; light-dark cycle: 7 a.m. to 7 p.m.) and were divided randomly into groups of seven. All test compounds were dissolved in DMSO and diluted to desired concentration with less than 1% DMSO. For the experiment, the test compound (IBMX, milrinone, MCPIP, mc1, mc2, mc5 or mc6) or solvent (control) was injected subcutaneously to mice at 1 mg/kg dosage twice a day (8:00 a.m. and 8:00 p.m.) for 7 days. On day 8, animals were anesthetized with intraperitoneal injection of thiopental (80 mg/kg) and blood samples were obtained from their hearts and then the liver was dissected. Each sample was centrifuged for 5 min and its serum was separated [3].
Alias3-Isobutyl-1-methylxanthine, 1-Methyl-3-Isobutylxanthine, Methylisobutylxanthine, Isobutylmethylxanthine
Chemical Properties
Molecular Weight222.24
FormulaC10H14N4O2
Cas No.28822-58-4
Storage & Solubility Information
Storagestore at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
H2O: 2.22mg/mL (10mM)
DMSO: 16.7 mg/mL(75 mM)
5% DMSO+95% Saline: 0.84 mg/mL (3.76 mM, precipitation)
Ethanol: 22.24mg/mL (100mM)
Solution Preparation Table
Ethanol/5% DMSO+95% Saline
1mg5mg10mg50mg
1 mM4.4996 mL22.4982 mL44.9964 mL224.9820 mL
Ethanol
1mg5mg10mg50mg
5 mM0.8999 mL4.4996 mL8.9993 mL44.9964 mL
10 mM0.4500 mL2.2498 mL4.4996 mL22.4982 mL
20 mM0.2250 mL1.1249 mL2.2498 mL11.2491 mL
50 mM0.0900 mL0.4500 mL0.8999 mL4.4996 mL
100 mM0.0450 mL0.2250 mL0.4500 mL2.2498 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords